Physician profile
John J Fitzpatrick
NPI 1952472813
$4,241.73
in general payments reported to CMS, 2019-2025
49 companies · $269 in 2025
The $269 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $278 · 2021: $903 · 2022: $706 · 2023: $1,141 · 2024: $598 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,007.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $632.99 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $425.28 | 2019-2024 | |
| Abbvie INC. | $350.51 | 2021-2025 | |
| Boston Scientific Corporation | $344.62 | 2021-2023 | Lux-Dx Insertable Cardiac Monitor |
| Novo Nordisk INC | $343.90 | 2020-2025 | Wegovy |
| Exact Sciences Corporation | $279.67 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.35 | 2021-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $132.39 | 2019-2024 | |
| Eisai INC. | $110.28 | 2020-2021 | |
| Amarin Pharma, INC. | $93.12 | 2019-2022 | |
| Astellas Pharma US INC | $88.34 | 2021-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $87.94 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $86.92 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $78.95 | 2023-2025 | Mounjaro, Zepbound, Kisunla |
| Lundbeck LLC | $64.29 | 2022-2024 | Rexulti |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fitzpatrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.